Biotech CEOs: Can Scientist-Founders Remain In Charge?
Biotech CEOs: Can Scientist-Founders Remain In Charge?
$200.00
Founder-CEOs do not typically remain at the helm as biotechs mature, as the majority of scientist-founders lack the skills to lead a company beyond discovery and early development. Exceptions to that rule are multiplying, though, especially in Europe as companies aim directly for Nasdaq. In this fascinating read, In Vivo reviews the many, varied paths toward biotech CEO, and what it takes to lead a company to IPO and beyond.
Author: Informa Pharma Intelligence
Publisher: InVivo
- Description
Taking a biotech public is not the obvious job for a scientist-founder CEO, yet plenty of US scientist-leaders have done IPOs, and in Europe as companies aim directly for Nasdaq. A new breed of scientist-founder has emerged – PhD-carrying entrepreneurs who want to personally help translate their ideas into companies, but investors will seek a CEO with more experience selling ideas to investors and potential partners. What does it take to stay the course from scientist-at-large to CEO? In Vivo reviews the many, varied paths toward biotech CEO, and what it takes to lead a company to IPO and beyond.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview –... 
Sign up to the